Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.
Chinese regulators have conditionally approved leading AI startup DeepSeek to purchase Nvidia's advanced H200 artificial intelligence chips, sources tell Reuters, as Beijing navigates competing pressures to advance its tech sector while managing geopolitical tensions.
The long-standing pillar of UK e-commerce—free and unlimited returns—is facing a fundamental overhaul as soaring costs and changing consumer habits force retailers to adopt more targeted and sustainable policies.
Robert Half International reports a pivotal return to sequential revenue growth in Q4 2025, signaling a potential turning point after a prolonged slump. However, the staffing giant continues to grapple with significant year-over-year declines, highlighting an uneven recovery path for the broader professional labor market.
Buoyed by record bookings and strong financial performance in 2025, Royal Caribbean Group projects double-digit revenue growth for 2026. The cruise giant announced a major fleet expansion, including a new 'Discovery Class' and ten additional river cruise ships, signaling confidence in sustained consumer appetite for experiential travel.
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.
PennyMac Financial Services capped a robust fiscal 2025 with Q4 net income of $107 million, overcoming headwinds from an unexpected wave of mortgage prepayments. While competitive pressures limited margin expansion, CEO David Spector pointed to strategic tech investments and a significant embedded refinance portfolio as catalysts for targeted mid-to-high teens ROE later this year.
While Sligro Food Group (AMS:SLIGR) shares have seen a modest 11% rebound in recent months, long-term investors are nursing significant losses, with the stock down 46% over five years. This deep dive examines the disconnect between the company's path to profitability and its languishing share price.
Tesla is pivoting its core strategy, phasing out legacy Model S and X production to mass-manufacture Optimus humanoid robots and deepening its commitment to artificial intelligence with a major investment in Elon Musk's xAI. This strategic realignment signals a future where the company's identity may evolve from electric vehicle pioneer to a broader AI and robotics powerhouse.
Amprius Technologies' shares have skyrocketed over 300% in the past year, driven by excitement around its silicon-anode battery technology. However, a deep dive into the company's financials reveals a significant valuation gap, raising questions about whether the stock's momentum has outpaced its fundamentals.
N-able shares have tumbled over 37% in the past year, lagging the broader software sector. A deep dive into cash flow and valuation metrics suggests the stock may be significantly undervalued, but investor sentiment remains deeply divided on its prospects.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
Dynatrace shares have tumbled over 34% in the past year, significantly underperforming the broader software sector. A deep dive into valuation metrics, including discounted cash flow and peer comparisons, suggests the stock may be trading at a substantial discount. We examine the numbers and the narrative shaping investor sentiment.
Shares of data security company Rubrik have faced significant pressure, declining over 25% in the past month. While the sell-off has pushed its valuation below some fair value estimates, analysts point to stiff competition and cautious IT spending as key headwinds. We examine whether the weakness presents a buying opportunity or a sign of deeper challenges.
